Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb.
We report that cytosine arabinoside (Ara-C), a cytosine analogue that at low doses causes phenotypical changes on human leukemia cells in vitro and in vivo, induces growth inhibition of oropharyngeal cancer KB and lung adenocarcinoma A549 cell lines. An increase in the number of epidermal growth factor and transferrin receptors (EGFR, TrfR) is induced by Ara-C on these cells. Maximal EGFR up-regulation occurs 96 h after the beginning of Ara-C exposure while maximal TrfR up-regulation is detected 24 h later. These effects occur without changes in the affinity of EGFR and TrfR for their ligands. Two classes of EGF-binding sites with a Kd of 0.055 nM and 2.3 nM respectively, and one class of transferrin-binding sites with a Kd of about 4 nM are detected on both untreated and Ara-C-treated KB cells. [3H]Thymidine uptake is clearly stimulated on KB cells by nanomolar concentrations of EGF and transferrin, whereas in Ara-C-treated cells [3H]thymidine uptake is not increased by EGF and transferrin under conditions where maximal EGFR and TrfR up-regulation occurs. The enhanced EGF and transferrin binding is paralleled by a twofold increase of in vitro targeting of Ara-C-treated KB and A549 cells with anti-EGFR 108.1 mAb and anti-TrfR OKT9 mAb. We propose that Ara-C could provide a new approach for the improvement of the therapeutic index of anti-EGFR and anti-TrfR immunoconjugates.
Cattedra di Oncologia Medica, Facoltà di Medicina, Università degli Studi Federico II di Napoli, Italy.
M
M
Caraglia
P
P
Tagliaferri
P
P
Correale
G
G
Genua
A
A
Pinto
S
S
Del Vecchio
G
G
Esposito
A R
AR
Bianco
D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000378:metabolism* / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D003561:Cytarabine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000378:metabolism*; D066246:ErbB Receptors / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D007457:Iodine Radioisotopes; D007624:KB Cells; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism; D009369:Neoplasms / Q000378:metabolism* / Q000628:therapy; D011863:Radioimmunoassay; D011956:Receptors, Cell Surface / Q000096:biosynthesis / Q000187:drug effects* / Q000276:immunology; D011990:Receptors, Transferrin / Q000096:biosynthesis / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D014168:Transferrin / Q000378:metabolism*; D014407:Tumor Cells, Cultured; D015854:Up-Regulation
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D011956:Receptors, Cell Surface; D011990:Receptors, Transferrin; D014168:Transferrin; D003561:Cytarabine; D004815:Epidermal Growth Factor; D066246:ErbB Receptors